Efficacy and Safety of Zanidatamab with Standard-of-care Therapy against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

This clinical trial is to see how well a new treatment works for people with HER2 biliary tract cancer, and is being tested a first option for those who have not yet received other treatments for their cancer.   

The treatment includes a drug called Zanidatamab given in combination with two chemotherapy medicines (Cisplatin and Gemcitabine).  Additionally some patients may also receive an immunotherapy to help the immune system fight the cancer (this will be either Durvalumab or Pembrolizumab). Doctors want to learn if adding this immune-based medicine improves results. 

This clinical trial is recruiting patient internationally.  The UK locations are:

• The Christie NHS Foundation Trust
  Manchester. M20 4BX
• Mount Vernon Cancer Centre
  London. HA 6 2RN
• NHS Foundation Trust Royal Marsden Hospital
  London. SW3 6JJ
• Royal Marsden Hospital NHS Foundation Trust
  Surrey. SM2 5PT
• Western General Hospital Edinburgh Cancer Centre
  Edinburgh. EH4 2XU

More details, including eligibility criteria and European locations can be found here at
ClinicalTrials.gov here: https://www.clinicaltrials.gov/study/NCT06282575

And on the NHS ‘Be part of Research’ website here:
https://bepartofresearch.nihr.ac.uk/trial-details/trial-detail?trialId=56374

Sponsor: Jazz Pharmaceuticals